StocksMedium•5 November 2026•
1 min read
Twist Bioscience Shares Slump 10% Following Critical Valuation Report
Key Facts
1Twist Bioscience shares fell 10% following a critical report questioning the company's valuation.
Twist Bioscience shares fell 10% following a critical report questioning the company's valuation. Investing.com reported that the sell-off was triggered by research raising concerns regarding the sustainability and justification of the company's current stock price levels.
TWST was trading at a low of $131.32 on November 5, 2026, after the stock closed at $142.58 on November 4, 2026. The intraday price action saw a high of $142.98 before the downward pressure intensified following the report's release.